Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23694373 | 0.95 | HDAC8 (0.33) | MAOBMAOAGABRB3GABRA2GABRB2 | |
| SCHEMBL5278793 | 0.94 | MAOB (0.38) | MAOBMAOA | |
| SCHEMBL5283823 | 0.93 | MAOB (0.34) | MAOBMAOAGABRB3 | |
| SCHEMBL5274900 | 0.90 | GABRB3 (0.39) | MAOAGABRB3GABRA2GABRB2 | |
| SCHEMBL5274867 | 0.89 | MAOB (0.37) | MAOBMAOAGABRB3 | |
| SCHEMBL5276085 | 0.87 | MAOB (0.33) | MAOBMAOAGABRB3 | |
| SCHEMBL5279446 | 0.87 | GABRB3 (0.39) | GABRB3GABRA2GABRB2 | |
| SCHEMBL5277118 | 0.86 | MAOB (0.35) | MAOBMAOA | |
| SCHEMBL5279807 | 0.84 | MAOB (0.32) | MAOB | |
| SCHEMBL5279680 | 0.84 | GABRB3 (0.33) | GABRB3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355230-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD59, CD58, CD2 | MAOB 3402/4885MAOA 2758/4885GABRB3 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.